A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
Launched by ELI LILLY AND COMPANY · Apr 15, 2010
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
Patients will be stratified according to baseline levels of serum triglycerides (\<150 or greater than or equal to 150 milligram/deciliter (mg/dL), HDL-C (\<45 or greater than or equal to 45 mg/dL for men; \<50 or greater than or equal to 50 mg/dL for women), and region (United States or Europe). After a diet lead-in and prior therapy washout phase, subjects meeting all entry criteria will be randomized to one of 10 double-blind treatment groups for a 12 week treatment phase. After randomization, patients will self-administer the study drugs once a day with a low fat meal as their first mea...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Diagnosed with Low High Density Lipoprotein Cholesterol (HDL-C) or hypercholesterolemia, after diet lead-in/washout of lipid therapies
- Exclusion Criteria:
- • History of coronary heart disease, or hardening of the arteries, or heart does not pump sufficiently well
- • Hypertension or high blood pressure that is not under control or your study physician does not consider the electrical activity of heart (Electrocardiogram \[ECG\]) to be compatible with participation in the study
- • History of a bad skin rash, a prior rash due to a drug or a history of chronic skin disorder (such as psoriasis or eczema)
- • Intolerance to certain lipid modifying drugs (including statins and Cholesteryl Ester Transfer Protein (CETP) inhibitors)
- • Not willing to stop taking prescription or over the counter drugs you use to control fats in your blood (like fish oil, niacin or statin) or pills to decrease your weight, including herbs
- • Not willing to follow the diet (low-fat) that the study physician will recommend
- • Have disease of liver, kidneys, muscles or other organs of body, a serious infection or cancer, or abnormal laboratory tests that study physician does not consider compatible with participation in the study
- • Breastfeeding woman or a woman who can still become pregnant, but are not willing to use a valid birth control measure to prevent pregnancies
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Houston, Texas, United States
Leipzig, , Germany
Cary, North Carolina, United States
Amsterdam, , Netherlands
Fayetteville, Arkansas, United States
Brandon, Florida, United States
Longwood, Florida, United States
Lexington, Kentucky, United States
Auburn, Maine, United States
Raleigh, North Carolina, United States
Winston Salem, North Carolina, United States
Bristol, Tennessee, United States
Kingsport, Tennessee, United States
Simpsonville, South Carolina, United States
Tacoma, Washington, United States
Vejle, , Denmark
Spring Valley, California, United States
Waterloo, Iowa, United States
Jacksonville, Florida, United States
Edison, New Jersey, United States
Greer, South Carolina, United States
Greensboro, North Carolina, United States
Hickory, North Carolina, United States
Philadelphia, Pennsylvania, United States
Picayune, Mississippi, United States
Salisbury, North Carolina, United States
Warsaw, , Poland
Wroclaw, , Poland
Berlin, , Germany
Indianapolis, Indiana, United States
Wilmington, North Carolina, United States
Wichita, Kansas, United States
San Diego, California, United States
Vista, California, United States
Golden, Colorado, United States
Ponte Vedra, Florida, United States
Baltimore, Maryland, United States
Endwell, New York, United States
Charlotte, North Carolina, United States
Red Lion, Pennsylvania, United States
Yardley, Pennsylvania, United States
Mount Pleasant, South Carolina, United States
Oregon, Wisconsin, United States
Ballerup, , Denmark
Bochum, , Germany
Breda, , Netherlands
Eindhoven, , Netherlands
Geleen, , Netherlands
Groningen, , Netherlands
Leiderdorp, , Netherlands
Rotterdam, , Netherlands
Zoetermeer, , Netherlands
Gdynia, , Poland
Reading, Berkshire, United Kingdom
Chorley, Lancashire, United Kingdom
Liverpool, Merseyside, United Kingdom
Glasgow, Scotland, United Kingdom
Birmingham, , United Kingdom
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials